Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 10:14:1223132.
doi: 10.3389/fphar.2023.1223132. eCollection 2023.

Is N-methylacetazolamide a possible new therapy against ischemia-reperfusion injury?

Alejandro Ciocci Pardo  1 , Leandro A Díaz Zegarra  1 , Luisa F González Arbeláez  1 , Ernesto A Aiello  1 , Susana M Mosca  1
Affiliations
Review

Is N-methylacetazolamide a possible new therapy against ischemia-reperfusion injury?

Alejandro Ciocci Pardo et al. Front Pharmacol. .

Abstract

The increase of intracellular Ca2+ concentration, produced principally by its influx through the L-type Ca2+ channels, is one of the major contributors to the ischemia-reperfusion injury. The inhibition of those channels in different experimental models was effective to ameliorate the post-ischemic damage. However, at a clinical level, the results were contradictory. Recent results of our group obtained in an ¨ex vivo¨ heart model demonstrated that a chemical derived from acetazolamide, the N-methylacetazolamide (NMA) protected the heart against ischemia-reperfusion injury, diminishing the infarct size and improving the post-ischemic recovery of myocardial function and mitochondrial dynamic. A significant inhibitory action on L-type Ca2+ channels was also detected after NMA treatment, suggesting this action as responsible for the beneficial effects on myocardium exerted by this compound. Although these results were promising, the effectiveness of NMA in the treatment of ischemic heart disease in humans as well as the advantages or disadvantages in comparison to the classic calcium antagonists needs to be investigated.

Keywords: L-type Ca2+ channel (CaL); N-methylacetazolamide; calcium; cardioprotection; myocardial ischaemia; reperfusion injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Schematic representation of L-type Ca2+ channel structure and its typical current in untreated and NMA treated hearts.
FIGURE 2
FIGURE 2
Possible pathway of the cardioprotection NMA-mediated.
See this image and copyright information in PMC

References

    1. Altamirano F., Wang Z. V., Hill J. A. (2015). Cardioprotection in ischaemia-reperfusion injury: novel mechanisms and clinical translation. J. Physiol. 593, 3773–3788. 10.1113/JP270953 - DOI - PMC - PubMed
    1. Anzell A. R., Maizy R., Przyklenk K., Sanderson T. H. (2018). Mitochondrial quality control and disease: insights into ischemia-reperfusion injury. Mol. Neurobiol. 55, 2547–2564. 10.1007/s12035-017-0503-9 - DOI - PMC - PubMed
    1. Baines C. P., Song C. X., Zheng Y. T., Wang G. W., Zhang J., Wang O. L., et al. (2003). Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ. Res. 92, 873–880. 10.1161/01.RES.0000069215.36389.8D - DOI - PMC - PubMed
    1. Barry W. H., Bridge J. H. (1993). Intracellular calcium homeostasis in cardiac myocytes. Circulation 87, 1806–1815. 10.1161/01.cir.87.6.1806 - DOI - PubMed
    1. Bauersachs R., Zeymer U., Brière J. B., Marre C., Bowrin K., Huelsebeck M. (2019). Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019, 8295054. 10.1155/2019/8295054 - DOI - PMC - PubMed